A strategic review concluded that the generics segment was misaligned with Wockhardt’s innovation agenda. Previous Post Anthem Biosciences IPO: GMP at 18% ahead of issue opening on Monday; Should you apply? Next Post Nine Pharma stocks that you should be watching out for ahead of Monday's trade Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email, and website in this browser for the next time I comment.Post Comment
